{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:50:48Z","timestamp":1782258648982,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","cysticfibrosisjournal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jcf.2024.11.004","type":"journal-article","created":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T02:22:32Z","timestamp":1732414952000},"page":"105-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Impact of elexacaftor\/tezacaftor\/ivacaftor on utilization of routine therapies in cystic fibrosis: Danish nationwide register study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7959-1548","authenticated-orcid":false,"given":"Hans Kristian","family":"R\u00e5ket","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Bj\u00f8rn","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1723-1342","authenticated-orcid":false,"given":"Joanna Nan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tacjana","family":"Pressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4000-210X","authenticated-orcid":false,"given":"Hanne Vebert","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Skov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Jensen-Fangel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen","family":"Jimenez-Solem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jcf.2024.11.004_bib0001","first-page":"6","volume":"39","author":"Aitken","year":"1993","journal-title":"Cystic fibrosis"},{"key":"10.1016\/j.jcf.2024.11.004_bib0002","series-title":"Cystic fibrosis, white book","year":"2022"},{"issue":"1","key":"10.1016\/j.jcf.2024.11.004_bib0003","first-page":"S5","article-title":"Increasing life expectancy in cystic fibrosis: advances and challenges","volume":"57","author":"McBennett","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1016\/j.jcf.2024.11.004_bib0004","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.004_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","author":"Burgel","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.004_bib0006","first-page":"1809","volume":"381","author":"Middleton","year":"2019"},{"issue":"5","key":"10.1016\/j.jcf.2024.11.004_bib0007","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: a clinical trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2024.11.004_bib0008","unstructured":"EMA. European medicines agency. 2020 [cited 2023 Nov 14]. Kaftrio. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kaftrio."},{"key":"10.1016\/j.jcf.2024.11.004_bib0009","unstructured":"Aftale sikrer patienter med cystisk fibrose nyeste behandling - Amgros [Danish] [Internet]. [cited 2023 Nov 14]. Available from: https:\/\/www.amgros.dk\/om-amgros\/nyheder\/aftale-sikrer-patienter-med-cystisk-fibrose-nyeste-behandling\/."},{"issue":"5","key":"10.1016\/j.jcf.2024.11.004_bib0010","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jcf.2019.11.007","article-title":"Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy","volume":"19","author":"Gifford","year":"2020","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2024.11.004_bib0011","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1002\/ppul.25361","article-title":"Assessment of treatment burden and complexity in cystic fibrosis: a quality improvement project","volume":"56","author":"Hente","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"167","key":"10.1016\/j.jcf.2024.11.004_bib0012","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0154-2022","article-title":"Role of inhaled antibiotics in the era of highly effective CFTR modulators","volume":"32","author":"Elborn","year":"2023","journal-title":"Eur Respi Rev"},{"issue":"6","key":"10.1016\/j.jcf.2024.11.004_bib0013","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment preference among people with cystic fibrosis","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.jcf.2024.11.004_bib0014","article-title":"Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals","volume":"9","author":"Almulhem","year":"2022","journal-title":"BMJ Open Respir Res"},{"issue":"6","key":"10.1016\/j.jcf.2024.11.004_bib0015","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jcf.2022.05.005","article-title":"Research letter: the impact of elexacaftor\/tezacaftor\/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis","volume":"21","author":"Song","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.004_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.27018","article-title":"Medication utilization and lung function changes after initiation of treatment with elexacaftor\/tezacaftor\/ivacaftor","author":"De Vuyst","year":"2024","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2024.11.004_bib0017","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2147\/CLEP.S179083","article-title":"The Danish health care system and epidemiological research: from health care contacts to database records","volume":"11","author":"Schmidt","year":"2019","journal-title":"CLEP"},{"key":"10.1016\/j.jcf.2024.11.004_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/apm.13375","article-title":"Close monitoring and early intervention: management principles for cystic fibrosis in Denmark","author":"Qvist","year":"2024","journal-title":"APMIS"},{"issue":"1","key":"10.1016\/j.jcf.2024.11.004_bib0019","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/bcpt.13472","article-title":"How patients in Denmark acquire their medicines: overview, data sources and implications for pharmacoepidemiology","volume":"128","author":"Jensen","year":"2021","journal-title":"Basic Clin Pharma Tox"},{"key":"10.1016\/j.jcf.2024.11.004_bib0020","unstructured":"Danish Medicines Agency [Internet]. [cited 2024 Aug 22]. Reimbursement thresholds. Available from: https:\/\/laegemiddelstyrelsen.dk\/en\/reimbursement\/calculate-reimbursement\/reimbursement-thresholds\/."},{"issue":"5","key":"10.1016\/j.jcf.2024.11.004_bib0021","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/apm.12915","article-title":"Cystic fibrosis - an example of personalized and precision medicine","volume":"127","author":"Skov","year":"2019","journal-title":"APMIS"},{"issue":"3","key":"10.1016\/j.jcf.2024.11.004_bib0022","first-page":"798","article-title":"Data Resource profile: the danish national prescription registry","volume":"46","author":"Potteg\u00e5rd","year":"2017","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jcf.2024.11.004_bib0023","unstructured":"Statens Serum Institut. Covid-19 timeline, 2020-2022 [Danish] [Internet]. [cited 2024 Aug 8]. Available from: https:\/\/www.ssi.dk\/media\/arkiv\/subsites\/covid19\/presse\/tidslinje-over-covid-19\/covid-19-tidslinje-lang-for-2020-2022-version-2-december-2022.pdf."},{"issue":"9","key":"10.1016\/j.jcf.2024.11.004_bib0024","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1136\/thoraxjnl-2020-216265","article-title":"Projecting the impact of triple CFTR modulator therapy on intravenous antibiotic requirements in cystic fibrosis using patient registry data combined with treatment effects from randomised trials","volume":"77","author":"Keogh","year":"2022","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.jcf.2024.11.004_bib0025","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/cid\/ciac117","article-title":"The rapid reduction of infection-related visits and antibiotic use among people with cystic fibrosis after starting elexacaftor-tezacaftor-ivacaftor","volume":"75","author":"Miller","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jcf.2024.11.004_bib0026","article-title":"The cost of simplifying treatments for cystic fibrosis: implications of the SIMPLIFY trial","volume":"30","author":"Gold","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"issue":"4","key":"10.1016\/j.jcf.2024.11.004_bib0027","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Mayer-Hamblett","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2024.11.004_bib0028","article-title":"Can people with cystic fibrosis safely stop taking some of their nebulised treatments if they are established on the new modulator therapy","year":"2024","journal-title":"Kaftrio?"},{"key":"10.1016\/j.jcf.2024.11.004_bib0029","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3310\/nihropenres.13384.1","article-title":"A grumbling concern: an international survey of gastrointestinal symptoms in cystic fibrosis in the modulator era","volume":"3","author":"Calthorpe","year":"2023","journal-title":"NIHR Open Res"},{"key":"10.1016\/j.jcf.2024.11.004_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.877118","article-title":"Elexacaftor-tezacaftor-ivacaftor treatment reduces abdominal symptoms in cystic fibrosis-early results obtained with the CF-specific CFAbd-score","volume":"13","author":"Mainz","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T22:11:51Z","timestamp":1738275111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324018137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1569199324018137"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.11.004","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of elexacaftor\/tezacaftor\/ivacaftor on utilization of routine therapies in cystic fibrosis: Danish nationwide register study","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.","name":"copyright","label":"Copyright"}]}}